Chemotherapy with or without radiation for p53-mutant endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial compares chemotherapy alone versus chemotherapy plus radiation therapy for people with endometrial cancer that has a p53 mutation. The goal is to see which approach better prevents the cancer from coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with endometrial cancer (stage I to IVA) and have already had surgery to remove the uterus and both fallopian tubes (lymph node evaluation was done).
- Tests on the tumor tissue show a p53 mutation (a specific genetic change).
- You have not had other cancer treatments (like chemotherapy, hormone therapy, or immunotherapy) in the 6 months before surgery.
- Your overall health is good enough for treatment: blood counts are in normal range, liver and kidney function are adequate, and you are able to care for yourself (Karnofsky score ≥60 or ECOG ≤2).
- You are not pregnant or nursing, and you do not have other active cancers or serious health conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether giving a short course of radiation together with chemotherapy can help treat endometrial cancer after surgery. It aims to find a treatment plan that is effective while keeping side effects manageable.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests whether taking a daily pill called olaparib after standard chemoradiation can help prevent endometrial cancer with a p53 mutation from coming back. Half of participants will receive olaparib, and the other half will just be watched closely.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This study looks at women with certain high-risk types of endometrial cancer that have not spread into the muscle wall of the uterus. It aims to understand how these cancers behave and whether lymph node testing is needed, which could help guide treatment decisions.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.